Teva backs full-year guidance despite Q3 sales miss
How Warren Buffett Triggered Teva's Epic Short Squeeze - New York Shock Exchange
Teva stock drops 10% as generics turnaround looks uncertain - MarketWatch
Teva Pharmaceutical Names Richard Francis as CEO, President - WSJ
TEVA -- Is Its Stock Price A Worthy Investment? Learn More.
TEVA — TradingView
Teva Generic Medicines Saved the United States $28.8 Billion in 2020, and a Total of $43.1 Billion Across Major Markets, According to Independent Analysis | Business Wire
Teva Tries to Put an End to the Opioid Wars - WSJ
Is Teva A Falling Drug Company Or A Great Value Proposition (NYSE:TEVA) | Seeking Alpha
Teva to acquire Mexico's Rimsa for $2.3 billion - MarketWatch
Drug maker Teva agrees to $4.3 billion national settlement over opioid lawsuits - MarketWatch
Teva Appoints New Chief Executive After Months of Speculation - WSJ
Teva Stock Soars After Reaching $4.25 Billion Opioid Settlement | Barron's
IBD Live at MarketWatch's Best New Ideas In Money Festival 2022 - Day 2 - YouTube
Teva in talks to buy Allergan's generics unit - MarketWatch
European Commission suspects pharma group Teva broke antitrust rules
Teva Pharmaceuticals - Wikiwand
Teva Pharmaceutical Industries - Updates, News, Events, Signals & Triggers
Teva: Avoid (NYSE:TEVA) | Seeking Alpha
Teva CEO Sees a Final Opioid Settlement Coming This Year | Barron's
Teva Pharmaceutical's Stock Tumbles on Outlook - WSJ
Teva's CEO on Why the Drugmaker Is Confident Despite Covid-19 | Barron's
TEVA — TradingView
Teva shares rise as company offers reassurance on former flagship drug Copaxone - MarketWatch
Teva beats first-quarter expectations but still has the same old problems - MarketWatch
Teva Pharmaceuticals - Wikiwand
